#034: June 9th, 2021 - Longevity Marketcap Telemetry

1. Announcements

2. Last Week in Longevity

3. Longevity Futures

4. Capital Raise Radar

5. Longevity Jobs

6. New Companies on Longevity List 

7. Non-Traditional

8. My Links

*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.

Mission: To grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan. 

If you want to be part of this mission alongside me, please consider supporting through Patreon or Longevity List Merch.

📢 Announcements 

• forum.longevitybase.org - A “StackExchange / Quora” for aging biology / longevity biotech. In open beta right now.Feel free to sign up and try it out. Email me if you would like to become a moderator or if you have some suggestions.

• The Longevity Biotech Show is officially a podcast! Check us out on Spotify and also Apple Podcasts.

• Longevity Virtual Coworking. Every Friday. Drop in hours: 12PM - 5PM EDT.If you are working on longevity or thinking about getting into the longevity industry, please join me for an experimental virtual longevity coworking space using the Pluto.Video web app. (No sign-up required.) (Room Link)  

• The 1% Bet for Longevity-- a website initiative.39 people have now signed up for the 1% Bet for Longevity Pledge. My goal is to get to 50,000 people and at least 100 companies to pledge 1% of their resources towards funding longevity companies and research by the end of the year. 

• Humans For Longevity. A project featuring a collection of stories from people who care about longevity and their motivations.

📝 Last Week in Longevity

Errata: The original version of this article incorrectly stated that Rubedo Life Science’s lead program was a “galacto-conjugate prodrug”. This has been corrected to “prodrug”.

• Biogen’s Alzheimer’s drug aducanumab gets FDA approval. On Monday, the FDA made a controversial decision to grant accelerated approval to Biogen’s aducanumab antibody therapy to treat Alzheimer’s disease. The approval is conditional on the requirement of Phase 4 trials that confirm aducanumab’s efficacy within nine years, or the approval could be rescinded by the FDA. This marks the first new drug approved for Alzheimer’s disease in 20 years.
  
  The approval was surprising. An independent expert committee convened last November voted overwhelmingly (10 objections, 1 abstain) against the approval of aducanumab, citing a failure to show strong evidence of its effectiveness to reduce cognitive decline. Biogen conducted two Phase